TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The FDA granted accelerated approval to Voceryq for adults with recurrent respiratory papillomatosis, a rare disease that causes wart-like growths in the airways. In the trial cited by the agency, 27% of a 26-patient subgroup had no excisions during 12 months of follow-up; postmarketing studies must verify the treatment’s clinical benefit.
The U.S. Food and Drug Administration has granted accelerated approval to Voceryq, a plasmid DNA-based immunotherapy intended to reduce the frequency of surgeries in adults with recurrent respiratory papillomatosis, a rare condition that causes wart-like growths in the airways. The approval offers a medical treatment option for a disease usually managed with repeat operations, but further studies are required to verify its clinical benefit.
The FDA based its decision on efficacy data from RRP-001, an open-label phase I/II trial involving 32 patients who had undergone at least two surgeries to remove growths in the year before treatment. Among the 26 patients with at least three prior surgeries in that period, seven—27%—had a complete response. The trial defined that outcome as needing no surgical excisions during 12 months of follow-up.
Voceryq combines two plasmids containing genetic coding for HPV proteins and interleukin 12. Patients’ healthy cells transcribe that coding to prompt an immune response against cells infected with HPV types 6 and 11, which cause recurrent respiratory papillomatosis. Treatment begins with surgical removal, or debulking, of visible growths, followed by four intramuscular doses given every three weeks.
The therapy is approved for use with the CELLECTRA 5PSP DNA medicine delivery device. FDA labeling warns of possible muscle contractions, transient bleeding and vasovagal reactions. Common adverse events reported in trials included injection-site reactions, headache, fatigue, hypertension, nausea and dizziness.
A Medical Option Alongside Repeat Surgery
Recurrent respiratory papillomatosis can require repeated procedures because growths may return after removal. The disease is caused by human papillomavirus and most often affects the larynx; in severe cases, growths can extend into the respiratory tract and make breathing difficult. Surgery can remove visible growths, but each operation carries risks, including possible laryngeal injury.
Voceryq is intended to lower the frequency of those operations, rather than to eliminate the disease. The trial’s complete-response result applies to a defined subgroup and a 12-month follow-up period; it does not establish that every patient will avoid further surgery. The approval matters because it adds another drug option for adults whose disease has required multiple procedures, while making the need for additional evidence explicit.
Popular right now
De'Longhi Dinamica Plus Fully Automatic Espresso Machine
Jura E6 Automatic Espresso Machine, Piano Black (15622)
Ninja CREAMi 7-in-1 Ice Cream Maker, NC301
As an affiliate, we earn on qualifying purchases.
From Surgical Care to Drug Options
There is no cure for recurrent respiratory papillomatosis, according to the source report. Treatment has commonly involved surgically removing papillomas when they recur. The condition’s effects vary: growths around the larynx can affect the voice, and more extensive disease may obstruct breathing.
Voceryq is not the first FDA-approved medical therapy for the condition. The FDA approved zopapogene imadenovec (Papzimeos) for recurrent respiratory papillomatosis in 2025, according to the report. Voceryq is described as the first FDA-approved recombinant plasmid DNA-based immunotherapy. Its accelerated approval is based on the cited trial data, with postmarketing trials required to verify and describe clinical benefit.
“The approval of Voceryq is an important step in improving the quality of life for RRP patients as every surgery carries the risk of laryngeal injury.”
— Simon Best, MD, Johns Hopkins University investigator, in a statement from Inovio Pharmaceuticals
Evidence Beyond the Initial Trial
The available report does not provide the full trial results for all 32 participants, detailed measures of response beyond the reported complete-response rate, or comparisons with another treatment. The 27% result is limited to the 26-person subgroup with at least three surgeries in the prior year and to the study’s 12-month follow-up definition.
Because the FDA granted accelerated approval, postmarketing trials are required to verify and describe clinical benefit. The report does not specify their design, enrollment targets or completion dates. It also does not establish how well Voceryq will work across patients with different disease severity or treatment histories.
Postmarketing Studies Must Confirm Benefit
The next evidence milestone is the required postmarketing research, which is intended to verify and further describe Voceryq’s clinical benefit. Those studies should help clarify the durability and extent of reduced surgery needs, although timelines and study details were not included in the report.
In the meantime, the approved regimen starts with surgical debulking and then gives four doses at three-week intervals, alongside the specified delivery device. Patients and clinicians will also need to weigh the potential benefit against the labeled warnings and reported adverse events. How widely the treatment is adopted, and whether it changes routine care, remains to be seen.
Key Questions
What is Voceryq approved to do?
The FDA approved Voceryq to reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis. The approval does not describe it as a cure.
What did the trial report?
In the RRP-001 trial, 27% of 26 patients who had at least three surgeries in the year before treatment had no surgical excisions during 12 months of follow-up. The trial included 32 patients overall.
How is the treatment given?
The regimen begins with surgical removal of visible growths, followed by four intramuscular doses given every three weeks. It is used with the CELLECTRA 5PSP delivery device.
What side effects were reported?
Common adverse events in trials included injection-site reactions, headache, fatigue, hypertension, nausea and dizziness. FDA labeling also warns of possible muscle contractions, transient bleeding and vasovagal reactions.
Is more research required?
Yes. The FDA requires postmarketing trials to verify and describe the treatment’s clinical benefit. The source report does not give details or timelines for those studies.
Source: medpagetoday.com
